IRLAB: Developing drug candidates with ‘blockbuster potential’ in Parkinson’s
Parkinson’s is the most common primary neurodegenerative disease after Alzheimer’s, affecting nearly nine million people around the world. This figure is expected to double by 2040 in line with an ageing population. Rooted in the Nobel Prize-winning research of Professor Arvid Carlsson, who was best known for his work exploring the role of the neurotransmitter dopamine in Parkinson’s, IRLAB, is developing innovative treatments to tackle unmet needs in Parkinson’s and other neurodegenerative conditions. Subscribe to read the full interview
Daily round-up: Friday 5th April
Welcome to your daily round-up of everything happening in the world of neurorehab.
Harmony Biosciences to trial narcolepsy drug in Prader-Willi syndrome
A new clinical trial will evaluate whether the drug candidate, [...]
Daily round-up: Thursday 4th April
Welcome to your daily round-up of everything happening in the world of neurorehab.
Awards to celebrate neuro rehab innovators
The prestigious NR Times Awards are back to shine a [...]
Awards to shed light on innovative neuro rehab research
The NR Times Awards, renowned for celebrating excellence in neurorehabilitation, [...]
Daily round-up: Thursday 28th March
Welcome to your daily round-up of everything happening in the world of neurorehab.
“I overcame the label of my disability and I help clients do the same”
Martin Gascoigne, founder and CEO of Neuro Case Management, the [...]
